{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:38:29Z","timestamp":1791401909761,"version":"4.3.3"},"reference-count":36,"publisher":"Wiley","issue":"22","license":[{"start":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T00:00:00Z","timestamp":1627344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["205678"],"award-info":[{"award-number":["205678"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2021,11,15]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>On the basis of the DREAMM\u20102 study (ClinicalTrials.gov identifier NCT03525678), single\u2010agent belantamab mafodotin (belamaf) was approved for patients with relapsed or refractory multiple myeloma (RRMM) who received \u22654 prior therapies, including anti\u2010CD38 therapy. The authors investigated longer term efficacy and safety outcomes in DREAMM\u20102 after 13 months of follow\u2010up among patients who received belamaf 2.5 mg\/kg.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>DREAMM\u20102 is an ongoing, phase 2, open\u2010label, 2\u2010arm study investigating belamaf (2.5 or 3.4 mg\/kg) in patients with RRMM who had disease progression after \u22653 lines of therapy and were refractory to immunomodulatory drugs and proteasome inhibitors and refractory and\/or intolerant to an anti\u2010CD38 therapy. The primary outcome was the proportion of patients that achieved an overall response, assessed by an independent review committee.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>As of January 31, 2020, 10% of patients still received belamaf 2.5 mg\/kg. Thirty\u2010one of 97 patients (32%; 97.5% confidence interval [CI], 21.7%\u201043.6%) achieved an overall response, and 18 responders achieved a very good partial response or better. Median estimated duration of response, overall survival, and progression\u2010free survival were 11.0 months (95% CI, 4.2 months to not reached), 13.7 months (95% CI, 9.9 months to not reached), and 2.8 months (95% CI, 1.6\u20103.6 months), respectively. Response and survival outcomes in patients who had high\u2010risk cytogenetics or renal impairment were consistent with outcomes in the overall population. Outcomes were poorer in patients with extramedullary disease. In patients who had a clinical response and prolonged dose delays (&gt;63 days; mainly because of corneal events), 88% maintained or deepened responses during their first prolonged dose delay. Overall, there were no new safety signals during this follow\u2010up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Extended follow\u2010up confirms sustained clinical activity without new safety signals with belamaf in this heavily pretreated patient population with RRMM.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.33809","type":"journal-article","created":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T09:28:51Z","timestamp":1627378131000},"page":"4198-4212","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":126,"title":["Longer term outcomes with single\u2010agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13\u2010month follow\u2010up from the pivotal DREAMM\u20102 study"],"prefix":"10.1002","volume":"127","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-9323","authenticated-orcid":false,"given":"Sagar","family":"Lonial","sequence":"first","affiliation":[{"name":"Winship Cancer Institute Emory University Atlanta Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans C.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1690-0188","authenticated-orcid":false,"given":"Ashraf","family":"Badros","sequence":"additional","affiliation":[{"name":"Greenebaum Cancer Center, Bone Marrow Transplant Program University of Maryland at Baltimore Baltimore Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Trudel","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Center Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4165-6869","authenticated-orcid":false,"given":"Ajay K.","family":"Nooka","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute Emory University Atlanta Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0405-7480","authenticated-orcid":false,"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al\u2010Ola","family":"Abdallah","sequence":"additional","affiliation":[{"name":"University of Kansas Cancer Center Fairway Kansas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Callander","sequence":"additional","affiliation":[{"name":"Carbone Cancer Center University of Wisconsin Madison Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Sborov","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute University of Utah Salt Lake City Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attaya","family":"Suvannasankha","sequence":"additional","affiliation":[{"name":"Indiana University Cancer Center Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology University Medical Center of Hamburg\u2010Eppendorf Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Voorhees","sequence":"additional","affiliation":[{"name":"Levine Cancer Institute Atrium Health Charlotte North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynsey","family":"Womersley","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Stockley Park United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"January","family":"Baron","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Upper Providence Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trisha","family":"Piontek","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Upper Providence Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lewis","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Research Triangle Park North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Opalinska","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Upper Providence Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Gupta","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Upper Providence Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam D.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, University of Pennsylvania Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,7,27]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903455"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000045"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010019\u20100435\u20107"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.621"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102016\u201001\u2010631200"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt483"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.06100616"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.22888"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.02.011"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.2217\/cpr.14.46"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102011\u201006\u2010358812"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899\u2010020\u201000568\u20103"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102013\u201010\u2010535088"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102016\u201001\u2010691162"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000560524.63281.bc"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(19)30788\u20100"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/bs.pmbts.2015.04.001"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2015.0064"},{"key":"e_1_2_9_20_1","unstructured":"US Food and Drug Administration (FDA).FDA granted accelerated approval to belantamab mafodotin\u2010blmf for multiple myeloma. Accessed December 14 2020.https:\/\/www.fda.gov\/drugs\/drug\u2010approvals\u2010and\u2010databases\/fda\u2010granted\u2010accelerated\u2010approval\u2010belantamab\u2010mafodotin\u2010blmf\u2010multiple\u2010myeloma"},{"key":"e_1_2_9_21_1","unstructured":"GlaxoSmithKline (GSK).GSK announces European Medicines Agency (EMA) accepted marketing authorisation application for belantamab mafodotin for the treatment of relapsed or refractory multiple myeloma. Accessed December 14 2020.https:\/\/www.gsk.com\/en\u2010gb\/media\/press\u2010releases\/gsk\u2010announces\u2010european\u2010medicines\u2010agency\u2010ema\u2010accepted\u2010marketing\u2010authorisation\u2010application\u2010for\u2010belantamab\u2010mafodotin\u2010for\u2010the\u2010treatment\u2010of\u2010relapsed\u2010or\u2010refractory\u2010multiple\u2010myeloma\/"},{"key":"e_1_2_9_22_1","unstructured":"GlaxoSmithKline.BLENREP prescribing information. Accessed December 14 2020.https:\/\/gsksource.com\/pharma\/content\/dam\/GlaxoSmithKline\/US\/en\/Prescribing_Information\/Blenrep\/pdf\/BLENREP\u2010PI\u2010MG.PDF"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8502"},{"key":"e_1_2_9_24_1","unstructured":"US Department of Health and Human Services National Institutes of Health National Cancer Institute.Common Terminology Criteria for Adverse Events (CTCAE). Version 4.03. Accessed March 3 2021.https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010\u201006\u201014_QuickReference_8.5x11.pdf"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.6084\/m9.figshare.12326546.v1"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(14)70442\u20105"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8536"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24402"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010020\u201000369\u20100"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.8015"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S15359"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102006\u201007\u2010038703"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129893"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS8552"},{"issue":"1","key":"e_1_2_9_35_1","first-page":"433","article-title":"DREAMM\u20104: evaluating safety and clinical activity of belantamab mafodotin in combination with pembrolizumab in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"4","author":"Nooka AK","year":"2020","journal-title":"Hemasphere"},{"key":"e_1_2_9_36_1","unstructured":"US Food and Drug Administration (FDA).FDA approves new treatment for refractory multiple myeloma [press release]. Accessed December 14 2020.https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/fda\u2010approves\u2010new\u2010treatment\u2010refractory\u2010multiple\u2010myeloma"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(20)32292\u20103"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.33809","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.33809","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.33809","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T17:20:54Z","timestamp":1760289654000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.33809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,27]]},"references-count":36,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2021,11,15]]}},"alternative-id":["10.1002\/cncr.33809"],"URL":"https:\/\/doi.org\/10.1002\/cncr.33809","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,27]]},"assertion":[{"value":"2021-03-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}